Table 3.

Multivariable analysis of Overall Survival and Time to CNS metastasis in Patients with BRAFV⁶⁰⁰ Mutations

	Overall Survival		Time to CNS Metastasis
Measure	Hazard Ratios (95% CI)	p-value	Hazard Ratios (95% CI)	p-value
Stage III status (IIIC v IIIB)	2 (0.9, 4.2)	0.09	1.4 (0.5, 3.7)	0.503
PTEN (Absent v Not Absent)	2.7 (1.3, 5.5)	0.008	4.2 (1.5, 12.0)	0.008
BRAF Inhibitor use (No v Yes)	3 (0.4, 23.3)	0.285	3 (0.4, 23.8)	0.299
Ipilimumab use (No v Yes)	1 (0.3, 3.0)	0.976	1.2 (0.4, 4.2)	0.741
Age	1 (1.0, 1.0)	0.549	1 (1.0, 1.0)	0.98
Gender (Male v Female)	1.5 (0.7, 3.8)	0.293	2.1 (0.7, 6.2)	0.179